Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2014, Article ID 621270, 6 pages
http://dx.doi.org/10.1155/2014/621270
Review Article

Cardiovascular Risk Factors in the Antiphospholipid Syndrome

1Escola Bahiana de Medicina e Saúde Pública, 40290-000 Salvador, BA, Brazil
2Rheumatology Division, Universidade Estadual do Rio de Janeiro, 20550-900 Rio de Janeiro, RJ, Brazil
3Rheumatology Division, Centro Médico do Hospital Aliança, 41810-080 Salvador, BA, Brazil

Received 25 March 2014; Revised 28 May 2014; Accepted 11 June 2014; Published 13 July 2014

Academic Editor: Yehuda Shoenfeld

Copyright © 2014 Felipe Freire da Silva et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Espinosa and R. Cervera, “Antiphospholipid syndrome,” Arthritis Research and Therapy, vol. 10, no. 6, article 230, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Ware Branch and A. G. Eller, “Antiphospholipid syndrome and thrombosis,” Clinical Obstetrics and Gynecology, vol. 49, no. 4, pp. 861–874, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. N. A. Sangle and K. J. Smock, “Antiphospholipid antibody syndrome,” Archives of Pathology & Laboratory Medicine, vol. 135, no. 9, pp. 1092–1096, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Espinosa and R. Cervera, “Antiphospholipid syndrome: frequency, main causes and risk factors of mortality,” Nature Reviews Rheumatology, vol. 6, no. 5, pp. 296–300, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. L. J. Jara, G. Medina, and O. Vera-Lastra, “Systemic antiphospholipid syndrome and atherosclerosis,” Clinical Reviews in Allergy and Immunology, vol. 32, no. 2, pp. 172–177, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Nyyssönen, S. Kurl, J. Karppi et al., “LDL oxidative modification and carotid atherosclerosis: results of a multicenter study,” Atherosclerosis, vol. 225, no. 1, pp. 231–236, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. T. D. Labecki, “Hyperchylomicronemia and hypercholesterolemia: their correlation with clinical atherosclerosis,” The American Journal of Clinical Nutrition, vol. 3, no. 2, pp. 132–140, 1955. View at Google Scholar · View at Scopus
  8. E. Matsuura, K. Kobayashi, M. Tabuchi, and L. R. Lopez, “Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis,” Progress in Lipid Research, vol. 45, no. 6, pp. 466–486, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Matsuura, G. R. V. Hughes, and M. A. Khamashta, “Oxidation of LDL and its clinical implication,” Autoimmunity Reviews, vol. 7, no. 7, pp. 558–566, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. J. George, A. Afek, B. Gilburd et al., “Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with β2-glycoprotein I,” Circulation, vol. 98, no. 11, pp. 1108–1115, 1998. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Afek, J. George, Y. Shoenfeld et al., “Enhancement of atherosclerosis in Beta-2-glycoprotein I-immunized apolipoprotein E-deficient mice,” Pathobiology, vol. 67, no. 1, pp. 19–25, 1999. View at Publisher · View at Google Scholar · View at Scopus
  12. J. George, A. Afek, B. Gilburd et al., “Atherosclerosis in LDL-receptor knockout mice is accelerated by immunization with anticardiolipin antibodies,” Lupus, vol. 6, no. 9, pp. 723–729, 1997. View at Google Scholar · View at Scopus
  13. P. Poredoš, “Intima-media thickness: Indicator of cardiovascular risk and measure of the extent of atherosclerosis,” Vascular Medicine, vol. 9, no. 1, pp. 46–54, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. C. C. Belizna, V. Richard, E. Primard et al., “Early atheroma in primary and secundary antiphospholipid syndrome: an intrinsic finding,” Seminars in Arthritis and Rheumatism, vol. 37, no. 6, pp. 373–380, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. P. R. J. Ames, A. Margarita, and J. D. Alves, “Antiphospholipid antibodies and atherosclerosis: insights from systemic lupus erythematosus and primary antiphospholipid syndrome,” Clinical Reviews in Allergy & Immunology, vol. 37, no. 1, pp. 29–35, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Medina, D. Casaos, L. J. Jara et al., “Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome,” Annals of the Rheumatic Diseases, vol. 62, no. 7, pp. 607–610, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Der, G. Kerekes, K. Veres et al., “Impaired endothelial function and increased carotid intima-media thickness in association with elevated von Willebrand antigen level in primary antiphospholipid syndrome,” Lupus, vol. 16, no. 7, pp. 497–503, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Margarita, J. Batuca, G. Scenna et al., “Subclinical atherosclerosis in primary antiphospholipid syndrome,” Annals of the New York Academy of Sciences, vol. 1108, pp. 475–80, 2007. View at Google Scholar
  19. S. Jiménez, M. A. García-Criado, D. Tàssies et al., “Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome,” Rheumatology, vol. 44, no. 6, pp. 756–761, 2005. View at Google Scholar
  20. F. Bilora, V. Boccioletti, B. Girolami et al., “Are antiphospholipid antibodies an independent risk factor for atherosclerosis?” Clinical and Applied Thrombosis/Hemostasis, vol. 8, no. 2, pp. 103–113, 2002. View at Google Scholar
  21. M. Charakida, J. P. Halcox, S. Sangle, D. D'Cruz, A. E. Donald, and C. G. Mackworth-Young, “Endothelial dysfunction and increased carotid intima-media thickness in primary antiphospholipid syndrome,” Journal of the American College of Cardiology, vol. 47, no. 4, p. 348, 2006. View at Google Scholar
  22. K. Sacré, B. Brihaye, F. Hyafil et al., “Asymptomatic myocardial ischemic disease in antiphospholipid syndrome: a controlled cardiac magnetic resonance imaging study,” Arthritis and Rheumatism, vol. 62, no. 7, pp. 2093–2100, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Vargas, A. Ricalde, A. Meave et al., “Endothelial dysfunction in patients with primary antiphospholipid syndrome (APS) demonstrated with positron emission tomography,” Arthritis and Rheumatology, vol. 50, supplement, article S74, 2004. View at Google Scholar
  24. N. Espinola-Zavaleta, E. Alexanderson-Rosas, N. Granados, M. E. Soto, and M. Amigo, “Myocardial perfusion defects in patients with autoimmune diseases: a prospective study. Analysis of two diagnostic tests,” Lupus, vol. 15, no. 1, pp. 38–43, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Szyper-Kravitz, A. Altman, J. F. de Carvalho et al., “Coexistence of the antiphospholipid syndrome and abdominal aortic aneurysm,” Israel Medical Association Journal, vol. 10, no. 1, pp. 48–51, 2008. View at Google Scholar · View at Scopus
  26. M. A. Barón, M. A. Khamashta, G. R. V. Hughes, and D. P. D'Cruz, “Prevalence of an abnormal ankle-brachial index in patients with primary antiphospholipid syndrome: preliminary data,” Annals of the Rheumatic Diseases, vol. 64, no. 1, pp. 144–146, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Medina-García, L. E. Molina-Carrión, U. Angeles-Garay, O. Vera-Lastra, and L. J. Jara-Quezada, “Cerebral flow abnormalities in primary antiphospholipid syndrome patients demonstrated by transcranial doppler. A controlled study,” The Journal of Rheumatology, vol. 33, abstract 73, p. 424, 2006. View at Google Scholar
  28. A. R. Ribeiro and J. F. Carvalho, “Fatores de risco tradicionais para doença cardiovascular na síndrome antifosfolípide primária comparada à secundária: um estudo de 96 pacientes,” Acta Reumatológica Portuguesa, vol. 35, no. 1, pp. 36–41, 2010. View at Google Scholar
  29. A. W. S. Souza, N. P. Silva, J. F. Carvalho, V. D. Almeida, M. A. E. Noguti, and E. I. Sato, “Impact of hypertension and hyperhomocysteinemia on arterial thrombosis in primary antiphospholipid syndrome,” Lupus, vol. 16, no. 10, pp. 782–787, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Erkan, Y. Yazici, M. G. Peterson, L. Sammaritano, and M. D. Lockshin, “A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome,” Rheumatology, vol. 41, no. 8, pp. 924–929, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Li, Y. S. Zhou, Y. Jia, and Z. G. Li, “Analysis of factors development of thrombosis in patients with syndrome,” Journal of Peking University, vol. 44, no. 5, pp. 788–791, 2012. View at Google Scholar
  32. J. A. Girón-González, E. G. Del Río, C. Rodríguez, J. Rodríguez-Martorell, and A. Serrano, “Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals,” The Journal of Rheumatology, vol. 31, pp. 1560–1567, 2004. View at Google Scholar
  33. A. A. Mehdi, I. Salti, and I. Uthman, “Antiphospholipid syndrome: endocrinologic manifestations and organ involvement,” Seminars in Thrombosis & Hemostasis, vol. 37, no. 1, pp. 49–57, 2011. View at Publisher · View at Google Scholar
  34. I. W. Uthman, I. Salti, and M. Khamashta, “Endocrinologic manifestations of the antiphospholipid syndrome,” Lupus, vol. 15, no. 8, pp. 485–489, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. D. S. Celermajer, K. E. Sorensen, D. Georgakopoulos et al., “Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults,” Circulation, vol. 88, no. 5, pp. 2149–2155, 1993. View at Publisher · View at Google Scholar · View at Scopus
  36. L. Rosenberg, D. W. Kaufman, S. P. Helmrich, and S. Shapiro, “The risk of myocardial infarction after quitting smoking in men under 55 years of age,” The New England Journal of Medicine, vol. 313, no. 24, pp. 1511–1514, 1985. View at Publisher · View at Google Scholar · View at Scopus
  37. J. F. De Carvalho, S. G. Pasoto, and S. Appenzeller, “Seizures in primary antiphospholipid syndrome: the relevance of smoking to stroke,” Clinical and Developmental Immunology, vol. 2012, Article ID 981519, 7 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. C. A. Caldas, L. M. H. da Mota, and J. F. de Carvalho, “Obesity in primary antiphospholipid syndrome is associated with worse outcome,” Joint Bone Spine, vol. 78, no. 3, pp. 324–325, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. K. Klack and J. F. Carvalho, “Importância da Intervenção Nutricional na Redução do Peso Corpóreo em Pacientes com Síndrome do Anticorpo Antifosfolípide,” Revista Brasileira de Reumatologia, vol. 48, no. 3, pp. 134–40, 2008. View at Google Scholar
  40. J. F. Carvalho, M. T. C. Caleiro, and E. Bonfá, “Hiper-homocisteinemia e síndrome antifosfolípide primária,” Revista Brasileira de Reumatologia, vol. 49, no. 4, pp. 337–345, 2009. View at Google Scholar
  41. H. Vannucchi and S. S. Melo, “Hiper-homocisteinemia e risco cardiometabólico,” Arquivos Brasileiros de Endocrinologia & Metabologia, vol. 53, no. 5, pp. 540–549, 2009. View at Google Scholar
  42. A. Rosada, U. Kassner, A. Vogt, M. Willhauck, K. Parhofer, and E. Steinhagen-Thiessen, “Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events?” Artificial Organs, vol. 38, no. 2, pp. 135–141, 2014. View at Publisher · View at Google Scholar
  43. R. Laczik, P. Szodoray, K. Veres et al., “Oxidized LDL induces in vitro lymphocyte activation in antiphospholipid syndrome,” Autoimmunity, vol. 43, no. 4, pp. 334–339, 2010. View at Publisher · View at Google Scholar
  44. M. Becarevic, S. Singh, and N. Majkic-Singh, “Oxidized LDL, anti-oxidized LDL and anti-annexin A5 antibodies in primary antiphospholipid syndrome,” Clinical Laboratory, vol. 54, no. 3-4, pp. 97–101, 2008. View at Google Scholar
  45. K. G. M. M. Alberti and P. Z. Zimmet, “Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation,” Diabetic Medicine, vol. 15, no. 7, pp. 539–553, 1998. View at Publisher · View at Google Scholar
  46. R. M. R. Pereira, J. F. Carvalho, and E. Bonfá, “Metabolic syndrome in rheumatological diseases,” Autoimmunity Reviews, vol. 8, no. 5, pp. 415–419, 2009. View at Publisher · View at Google Scholar
  47. C. E. M. Rodrigues, E. Bonfá, M. T. C. Caleiro et al., “Association of arterial events with the coexistence of metabolic syndrome and primary antiphospholipid syndrome,” Arthritis Care and Research, vol. 64, no. 10, pp. 1576–1583, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. C. E. M. Rodrigues, M. B. Vendramini, C. Bueno, E. Bonfá, and J. F. Carvalho, “Adipocytokines in primary antiphospholipid syndrome: potential markers of low-grade inflammation, insulin resistance and metabolic syndrome,” Clinical and Experimental Rheumatology, vol. 30, pp. 871–878, 2012. View at Google Scholar
  49. H. S. Mattu and H. S. Randeva, “Role of adipokines in cardiovascular disease,” Journal of Endocrinology, vol. 216, no. 1, pp. T17–T36, 2013. View at Publisher · View at Google Scholar · View at Scopus